Terms: = Prostate cancer AND ELN, ENSG00000049540, 2006, WS, WBS, SVAS, FLJ43523, FLJ38671 AND Treatment
760 results:
1. Safety of high-dose rate (HDR) brachytherapy for patients with prostate cancer and history of prior chemoradiation for rectal cancer: A case series.
Thomas H; Chen JJ; Abdul-Baki H; Sabbagh A; Shaheen H; Chau OW; Malik N; Ayoub A; Hassanzadeh C; Hsu IC; Mohamad O
Brachytherapy; 2024; 23(2):173-178. PubMed ID: 38160102
[TBL] [Abstract] [Full Text] [Related]
2. Expression and gene regulatory network of S100A16 protein in cervical cancer cells based on data mining.
Zhang H; Yang Y; Xing W; Li Y; Zhang S
BMC Cancer; 2023 Nov; 23(1):1124. PubMed ID: 37978469
[TBL] [Abstract] [Full Text] [Related]
3. prostate cancer treatment in Portugal: a nationwide analysis.
Botelho F; Lopes R; Pina F; Silva C; Pacheco-Figueiredo L; Lunet N
Sci Rep; 2023 Nov; 13(1):19362. PubMed ID: 37938598
[TBL] [Abstract] [Full Text] [Related]
4. Mortality Risk for Docetaxel-Treated, High-Grade prostate cancer With Low PSA Levels: A Meta-Analysis.
Mahal BA; Kwak L; Xie W; Eastham JA; James ND; Sandler HM; Feng FY; Brihoum M; Fizazi K; Sweeney C; Ravi P; D'Amico AV
JAMA Netw Open; 2023 Nov; 6(11):e2340787. PubMed ID: 37910103
[TBL] [Abstract] [Full Text] [Related]
5. Long-term Overall Survival after External Beam Radiotherapy for Localised prostate cancer.
Jahreiβ MC; Incrocci L; Dirkx M; de Vries KC; Aben KKH; Bangma C; Heemsbergen WD
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e689-e698. PubMed ID: 37852813
[TBL] [Abstract] [Full Text] [Related]
6. Long term efficacy of prosthetic inguinal herniorrhaphy concomitant with robot-assisted laparoscopic radical prostatectomy.
Peixoto N; Grobet-Jeandin E; Schoofs F; Windisch O; Iselin C; Benamran D
World J Urol; 2023 Nov; 41(11):3169-3174. PubMed ID: 37755521
[TBL] [Abstract] [Full Text] [Related]
7. Genome-wide methylation profiling of diagnostic tumor specimens identified DNA methylation markers associated with metastasis among men with untreated localized prostate cancer.
Chao CR; Slezak J; Siegmund K; Cannavale K; Shu YH; Chien GW; Chen XF; Shi F; Song N; Van Den Eeden SK; Huang J
Cancer Med; 2023 Sep; 12(18):18837-18849. PubMed ID: 37694549
[TBL] [Abstract] [Full Text] [Related]
8. Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.
Tseng CH
Front Endocrinol (Lausanne); 2023; 14():1185053. PubMed ID: 37560306
[TBL] [Abstract] [Full Text] [Related]
9. Utilization of diabetes self-management program among breast, prostate, and colorectal cancer survivors: Using 2006-2019 Texas Medicare data.
Lee WC; Digbeu BDE; Serag H; Sallam H; Kuo YF
PLoS One; 2023; 18(7):e0289268. PubMed ID: 37498914
[TBL] [Abstract] [Full Text] [Related]
10. External validation of a risk model predicting failure of salvage focal ablation for prostate cancer.
Light A; Peters M; Reddy D; Kanthabalan A; Otieno M; Pavlou M; Omar R; Adeleke S; Giganti F; Brew-Graves C; Williams NR; Emara A; Haroon A; Latifoltojar A; Sidhu H; Freeman A; Orczyk C; Nikapota A; Dudderidge T; Hindley RG; Virdi J; Arya M; Payne H; Mitra AV; Bomanji J; Winkler M; Horan G; Moore C; Emberton M; Punwani S; Ahmed HU; Shah TT
BJU Int; 2023 Nov; 132(5):520-530. PubMed ID: 37385981
[TBL] [Abstract] [Full Text] [Related]
11. Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer.
Pellegrino A; Gandaglia G; de Angelis M; Fallara G; Mazzone E; Stabile A; Pellegrino F; Robesti D; Leni R; Scuderi S; Cucchiara V; Cirulli GO; Barletta F; Montorsi F; Briganti A
World J Urol; 2023 Aug; 41(8):2069-2076. PubMed ID: 37326656
[TBL] [Abstract] [Full Text] [Related]
12. [Risk Factors of Antiresorptive Agent-Related Osteonecrosis of the Jaw in prostate cancer Patients with Bone Metastases].
Ito K; Iijima H; Kumagai M; Yabusaki R; Muro Y; Shiraishi Y; Imamura M; Yoshimura K
Hinyokika Kiyo; 2023 May; 69(5):125-129. PubMed ID: 37312492
[TBL] [Abstract] [Full Text] [Related]
13. Impact of cancer and other causes of death on mortality of cancer patients: A study based on Japanese population-based registry data.
Charvat H; Fukui K; Matsuda T; Katanoda K; Ito Y
Int J Cancer; 2023 Sep; 153(6):1162-1171. PubMed ID: 37278616
[TBL] [Abstract] [Full Text] [Related]
14. Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine prostate cancer Coexisting with Androgen Receptor Pathway prostate cancer.
Watanabe R; Miura N; Kurata M; Kitazawa R; Kikugawa T; Saika T
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240308
[TBL] [Abstract] [Full Text] [Related]
15. Seed Density as a New Predictive Index of Seed Migration in Brachytherapy for prostate cancer Using Iodine-125 Loose Seed.
Yamaguchi T; Matsuo M; Mori T; Noda Y; Makita C; Hyodo F; Iinuma K; Nakano M; Koie T; Tanaka H
Curr Oncol; 2023 Apr; 30(4):4060-4066. PubMed ID: 37185421
[TBL] [Abstract] [Full Text] [Related]
16. Evaluation of Outcomes Following Focal Ablative Therapy for treatment of Localized Clinically Significant prostate cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-Year Experience.
Habashy D; Reddy D; Peters M; Shah TT; van Son M; van Rossum PSN; Tanaka MB; Cullen E; Engle R; McCracken S; Greene D; Hindley RG; Emara A; Nigam R; Orczyk C; Shergill I; Persad R; Virdi J; Moore CM; Arya M; Winkler M; Emberton M; Ahmed HU; Dudderidge T
J Urol; 2023 Jul; 210(1):108-116. PubMed ID: 37014172
[TBL] [Abstract] [Full Text] [Related]
17. Advances in radiotherapy and its impact on second primary cancer risk: A multi-center cohort study in prostate cancer patients.
Jahreiß MC; Hoogeman M; Aben KK; Dirkx M; Snieders R; Pos FJ; Janssen T; Dekker A; Vanneste B; Minken A; Hoekstra C; Smeenk RJ; Incrocci L; Heemsbergen WD
Radiother Oncol; 2023 Jun; 183():109659. PubMed ID: 37003369
[TBL] [Abstract] [Full Text] [Related]
18. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
[TBL] [Abstract] [Full Text] [Related]
19. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent prostate cancer Following Radical prostatectomy.
Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
[TBL] [Abstract] [Full Text] [Related]
20. Adoption of Lutetium-
Flegar L; Thoduka SG; Librizzi D; Luster M; Zacharis A; Heers H; Eisenmenger N; Ahmadzadehfar H; Eiber M; Weber W; Groeben C; Huber J
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2188-2195. PubMed ID: 36826478
[TBL] [Abstract] [Full Text] [Related]
[Next]
